Whalesbook
Aakhir stock kyu bhaga jab profit kam ho gaya?
Simple logic yeh hai ki investors ne company ke haalat se zyada uske future par dhyaan diya hai. Syngene International ke shares ne Thursday ko 8.21% ki tezadi pakdi aur ₹467.65 par band hue. Yeh sab tab hua jab company ne Q4 FY26 aur poore saal FY26 ke results announce kiye.
Revenue mein thodi badhotri dikhi, Q4 mein yeh 1.8% badhkar ₹1,036.5 crore ho gaya aur poore saal ke liye 2.6% badhkar ₹3,738.7 crore. Lekin profit after tax (PAT) ki baat karein toh yeh Q4 mein 19.3% aur poore saal mein 36.2% gir gaya, kramashah ₹147.9 crore aur ₹316.7 crore par aa gaya. EBITDA margins bhi kaafi kam ho gaye, Q4 mein 30.8% ho gaye jo pehle 35% the, aur poore saal ke liye 26% ho gaye jo pehle 30% the.
CRDMO Sector ki Race aur Syngene ka Future
India ka CRDMO sector bahut jaldi badhne wala hai, lagbhag $22-$25 billion tak 2035 tak pahunch sakta hai. Iska reason hai global supply chains mein changes aur Antibody-Drug Conjugates (ADCs) jaise complex treatments ka rise. Syngene ne apna naya ADC discovery lab operational kar liya hai, jo ise is trend ka fayda uthane mein help karega. Lonza Group aur WuXi AppTec jaise competitors bhi expand kar rahe hain, lekin Syngene ke integrated services ek badi strength hai.
Profitability ki Problem aur Valuation ka Chakkar
Syngene ko profitability ko lekar kaafi mushkil ho rahi hai. Ek bade client par zyada depend karne ki wajah se revenue aur margins par pressure hai, aur company ko lagta hai ki yeh situation aage bhi rah sakti hai. Naye facilities aur employee expenses jaise operational costs bhi margins ko tight kar rahe hain. Stock ka valuation 50-54 ke P/E ratio ke aas-paas hai, jo future growth ke liye price kiya gaya hai, lekin haal ke earnings isse match nahi kar rahe. Pichhle saal stock 29% gir bhi chuka hai, jo dikhata hai ki sector growth ko profits mein badalne mein company struggle kar rahi hai.
Analysts Kya Kehte Hain?
Analysts thode confident hain, 8 ne 'Buy' rating di hai aur average price target ₹603.75 rakha hai. Macquarie ne 'Outperform' rating ke saath target ₹835 diya hai. Par valuation aur sustained profits ko lekar chintaayein bhi hain. Naye leaders, jaise Siddharth Mittal (jo pehle Biocon mein the) aur Kiran Mazumdar-Shaw (Executive Chairperson ban gayi hain), ko yeh profit challenges solve karni hongi aur revenue diversify karna hoga.